-+ 0.00%
-+ 0.00%
-+ 0.00%

Bellevue sees medtech sector offering upside as valuations hit historic lows

PUBT·04/28/2026 13:46:57
Listen to the news
Bellevue sees medtech sector offering upside as valuations hit historic lows
  • Bellevue said Q1 2026 earnings season reset expectations for medtech and services, easing pressure from falling valuation multiples and weak sentiment.
  • Stock reactions to results signaled improved risk appetite, with Boston Scientific up 9% and Intuitive Surgical up 7%.
  • Consensus estimates now look more realistic, with headwinds easing from China volume-based pricing pressure and US Medicare Advantage reimbursement uncertainty.
  • Bellevue pegged sector forward P/E at about 20x, near historical lows, leaving medtech valued roughly in line with broader market despite intact fundamentals.
  • Outlook calls for profit growth to shift toward margin expansion and free cash flow as innovation-driven demand continues in areas such as robotic surgery and pulsed field ablation.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bellevue Group AG published the original content used to generate this news brief on April 28, 2026, and is solely responsible for the information contained therein.